Property	Value
Status
Version
Ad File
Disable Ads Flag
Environment
Moat Init
Moat Ready
Contextual Ready
Contextual URL
Contextual Initial Segments
Contextual Used Segments
AdUnit
SubAdUnit
Custom Targeting
Ad Events
Invalid Ad Sizes

Sara M. Tolaney MD, MPH Advisory Board

Benjamin O. Anderson MD, FACS Advisory Board

Lee S. Schwartzberg MD, FACP Advisory Board

See All Experts

featured

Published in Oncology and

Expert Opinion / Interview · March 04, 2021

Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCC

Interview by

Sumanta Kumar Pal MD

Interview with

Jun Gong MD

Save Recommend

Sign in to PracticeUpdate

Only registered members have full access to PracticeUpdate content.

Sign in

Not a member?

Join for free

Additional Info

Disclosures

Disclosure statements are available on the authors' profiles:

Jun Gong MD

Sumanta Pal MD

featured

The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges

Lancet · November 27, 2024
featured

Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer

Lancet Oncol · November 26, 2024

updated
featured

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Blood · November 26, 2024

updated
story of the week

Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphoma

Lancet Oncol · November 25, 2024

updated
featured

Clinical Outcomes in Patients With T4 and/or N2 Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

Clin Colorectal Cancer · November 21, 2024
featured

Valemetostat Monotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma

Lancet Oncol · November 20, 2024
story of the week

Efficacy of Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

N. Engl. J. Med · November 18, 2024
story of the week

Stereotactic Body Radiotherapy for Localized Prostate Cancer

N. Engl. J. Med · November 16, 2024

updated
featured

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

N. Engl. J. Med · November 15, 2024

updated
story of the week

Nivolumab Plus AVD for Advanced-Stage Classic Hodgkin's Lymphoma

N. Engl. J. Med · November 13, 2024
featured

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Clin. Cancer Res · November 12, 2024

Renal Cell Carcinoma

Longer Term Outcomes With Pembrolizumab Plus Axitinib for Advanced RCC

Additional Info

Further Reading

The Lancet Breast Cancer Commission: Evidence-Based Roadmap to Address Urgent Global Breast Cancer Challenges

Next-Generation Oral SERD Camizestrant vs Fulvestrant in Postmenopausal ER+/HER2− Advanced Breast Cancer

Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma

Valemetostat for Relapsed or Refractory Peripheral T-Cell Lymphoma

Clinical Outcomes in Patients With T4 and/or N2 Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy

Valemetostat Monotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma

Efficacy of Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer

Stereotactic Body Radiotherapy for Localized Prostate Cancer

Efficacy of Durvalumab After Chemoradiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

Nivolumab Plus AVD for Advanced-Stage Classic Hodgkin's Lymphoma

Efficacy and Safety of Elacestrant in ER+/HER2− MBC With ESR1-Mutated Tumors Based on Prior Duration of Endocrine Therapy Plus CDK4/6i and in Clinical Subgroups

Related Videos